0001127602-22-022683.txt : 20220919 0001127602-22-022683.hdr.sgml : 20220919 20220919163936 ACCESSION NUMBER: 0001127602-22-022683 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220915 FILED AS OF DATE: 20220919 DATE AS OF CHANGE: 20220919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Basil Michelle L CENTRAL INDEX KEY: 0001699629 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 221251001 MAIL ADDRESS: STREET 1: HAEMONETICS CORPORATION STREET 2: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0401 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-09-15 0000313143 HAEMONETICS CORP HAE 0001699629 Basil Michelle L 125 SUMMER STREET BOSTON MA 02110 1 EVP and General Counsel Common Stock 2022-09-15 4 M 0 11154 38.43 A 51789 D Common Stock 2022-09-15 4 M 0 14231 41.64 A 66020 D Common Stock 2022-09-15 4 M 0 3173 56.57 A 69193 D Common Stock 2022-09-15 4 S 0 27769 77.76 D 41424 D Common Stock 2022-09-15 4 S 0 6029 78.50 D 35395 D Non-qualified Stock Option (Right to Buy) 38.43 2022-09-15 4 M 0 11154 0 D 2018-03-06 2024-03-06 Common Stock 11154 3464 D Non-qualified Stock Option (Right to Buy) 41.64 2022-09-15 4 M 0 14231 0 D 2018-06-06 2024-06-06 Common Stock 14231 4213 D Non-qualified Stock Option (Right to Buy) 56.57 2022-09-15 4 M 0 3173 0 D 2028-05-18 Common Stock 3173 13564 D Transaction pursuant to an existing 10b5-1 trading plan. This number includes unvested restricted stock units ("RSUs") previously reported. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.33 to $78.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $78.85, inclusive. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. /s/ Michelle L. Basil 2022-09-19